The pharmaceutical industry is witnessing significant developments, including Merck's forecasted revenue surge to $70 billion ...
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...
Employer-sponsored insurance continues to cover the majority of Americans, but employers are facing mounting cost pressures ...
The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds. Analysts at Piper Sandler have reaffirmed their ‘Overweight’ rating on BridgeBio Pharma ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Particle Dynamics, a provider of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback